Core Viewpoint - ST Xiangxue (300147) has received an administrative penalty decision from the China Securities Regulatory Commission (CSRC) due to information disclosure violations, with some penalties being reduced compared to the prior notice [1] Regulatory Actions - The administrative penalty decision no longer imposes a 5-year market ban on the actual controller Wang Yonghui and removes the warning and 500,000 yuan fine against the former independent director Hao Shiming, while other penalties remain consistent with the prior notice [1] Corporate Restructuring - The Guangzhou Intermediate People's Court has agreed to extend the company's pre-restructuring period until October 11, 2025, during which the company will actively cooperate with the temporary administrator and the court [1] - The company has publicly appointed auditing, evaluation, and financial advisory intermediaries, with the auditing and evaluation work progressing smoothly [1] Business Operations - The company emphasizes the clinical value and market potential of TAEST16001 and is fully advancing the preparatory work for confirmatory clinical trials, with updates to be disclosed according to clinical developments and information disclosure rules [1]

证券代码:300147 证券简称: 香雪制药 公告编号:2025-038 广州市香雪制药股份有限公司 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 雪制药"）及公司实际控制人王永辉收到中国证券监督管理委员会（以下简称"中 国证监会"）下发的《立案告知书》（编号：证监会立案字 0062024028 号、编 号：证监会立案字 0062024029 号），因涉嫌信息披露违法违规，根据《中华人 民共和国证券法》、《中华人民共和国行政处罚法》等法律法规，中国证监会决 定对公司及王永辉立案。2025 年 3 月 21 日，公司收到中国证监会发出的《行政 处罚事先告知书》（广东证监处罚字〔2025〕5 号）。以上具体内容详见公司分 别于 2024 年 9 月 30 日、2025 年 3 月 21 日在巨潮资讯网披露的《关于公司及实 际控制人收到中国证券监督管理委员会立案告知书的公告》 （公告编号:2024-051） 和《关于公司及相关当事人收到 <行政处罚事先告知书> 的公告》 （公告编号:2025- 近日，公司及相关当事人收到中国证券监督管理委员会广东监管局发出的 《行 ...

证券代码:300147 证券简称: 香雪制药 公告编号:2025-038 广州市香雪制药股份有限公司 关于公司及相关当事人收到《行政处罚决定书》的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 2024 年 9 月 30 日，广州市香雪制药股份有限公司（以下简称"公司"、"香 雪制药"）及公司实际控制人王永辉收到中国证券监督管理委员会（以下简称"中 国证监会"）下发的《立案告知书》（编号：证监会立案字 0062024028 号、编 号：证监会立案字 0062024029 号），因涉嫌信息披露违法违规，根据《中华人 民共和国证券法》、《中华人民共和国行政处罚法》等法律法规，中国证监会决 定对公司及王永辉立案。2025 年 3 月 21 日，公司收到中国证监会发出的《行政 处罚事先告知书》（广东证监处罚字〔2025〕5 号）。以上具体内容详见公司分 别于 2024 年 9 月 30 日、2025 年 3 月 21 日在巨潮资讯网披露的《关于公司及实 际控制人收到中国证券监督管理委员会立案告知书的公告》（公告编号:2024-051） 和《关于公司及相关当事人收 ...

ST香雪（300147.SZ）8月14日在投资者互动平台表示，截至回复日，公司尚未收到中国证监会广东监 管局出具的《行政处罚决定书》。 每经AI快讯，有投资者在投资者互动平台提问：请问目前处罚申述进展如何？ （文章来源：每日经济新闻） ...

人民财讯8月13日电，企查查APP显示，近日，北京杜德生物科技有限公司成立，注册资本1000万元， 经营范围包含：第二类医疗器械销售；人体基因诊断与治疗技术开发；工程和技术研究和试验发展；生 物化工产品技术研发等。企查查股权穿透显示，该公司由广州杜德生物科技有限公司等共同持股，后者 大股东为ST香雪（300147）。 ...

Group 1 - The stock price of ST Xiangxue (300147) closed at 7.68 yuan on August 11, 2025, down 1.29% with a turnover rate of 2.05% and a trading volume of 134,500 hands, amounting to 103 million yuan [1] - The latest financial report for ST Xiangxue shows total operating revenue of 421 million yuan for Q1 2025, a year-on-year decrease of 25.99%, and a net profit attributable to shareholders of 87.73 million yuan, down 146.03% year-on-year [1] - The company has a current ratio of 0.277, a quick ratio of 0.223, and a debt-to-asset ratio of 81.75% [1] Group 2 - ST Xiangxue has made investments in 40 enterprises and participated in 2,157 bidding projects [2] - The company holds 244 trademark registrations and 165 patent registrations, along with 251 administrative licenses [2]

Core Viewpoint - The company emphasizes the clinical value and market potential of its new drug TAEST16001 and is actively advancing the preparatory phase of confirmatory clinical trials [2]. Group 1 - The company is committed to keeping investors informed about the clinical progress of TAEST16001 and the status of its pre-restructuring efforts [2]. - The company plans to disclose updates regarding the new drug development and pre-restructuring progress in accordance with information disclosure regulations [2]. - Investors are encouraged to pay attention to the company's announcements for further details [2].

Core Viewpoint - The company confirmed that the clinical trial protocol for TAEST16001 includes clear standards for tumor antigen expression detection in target patients, but does not utilize organoid models for patient screening or efficacy validation [1] Group 1 - The clinical trial for TAEST16001 is a TCR-T cell therapy targeting tumor antigens [1] - The company has established specific criteria for detecting tumor antigen expression in patients during the Phase II clinical trial [1] - No organoid models or similar technologies are employed for patient selection or efficacy validation in the related studies [1]

Group 1 - The Anhui Provincial Drug Supervision Administration announced that a product from Bozhou Huqiao Pharmaceutical Co., Ltd. (a subsidiary of Guangzhou Xiangxue Pharmaceutical Co., Ltd.) failed to meet quality standards, specifically regarding its characteristics [1][2] - The announcement revealed that a total of 15 varieties and 16 batches of drugs were found non-compliant with standards, including issues related to characteristics, total ash, dissolution rate, moisture, weight variation, and identification [1] - The specific product in question, Winter Melon Seed, was sampled from Susong County Traditional Chinese Medicine Hospital, with the batch number 1901070142, and was tested against the Anhui Province Chinese Medicine Decoction Pieces Processing Specification 2015 edition [1][3] Group 2 - Huqiao Pharmaceutical was established on December 21, 2010, and is primarily engaged in the production and sale of traditional Chinese medicine pieces, including toxic pieces, as well as other food products [2] - Xiangxue Pharmaceutical holds a 70% stake in Huqiao Pharmaceutical and has been recognized as a leading enterprise in the modernization of traditional Chinese medicine, focusing on various health-related sectors [2]

Core Viewpoint - The antiviral oral liquid market is experiencing significant growth driven by the rising incidence of viral diseases and increasing health awareness among consumers, with a projected market size increase from 1.1 billion yuan in 2020 to 1.469 billion yuan in 2024, reflecting a compound annual growth rate of 7.5% [1][12]. Industry Overview - Antiviral oral liquids are common traditional Chinese medicine formulations, primarily composed of ingredients like Banlangen, Shigao, and Lugen, used for treating viral infections such as influenza and respiratory infections [3][5]. - The industry has evolved since the 1980s, transitioning from basic herbal formulations to more sophisticated products due to technological advancements, leading to improved efficacy and safety [5]. Market Dynamics - The demand for antiviral oral liquids is increasing due to the high prevalence of viral diseases and an aging population, alongside a shift in consumer perception of these products as essential for daily health protection [1][12]. - The rise of e-commerce platforms has further facilitated market growth by providing convenient access to these products [1][12]. Industry Chain - The industry chain consists of upstream raw material cultivation, production equipment, and packaging materials; midstream involves the manufacturing of antiviral oral liquids; and downstream includes sales through hospitals, pharmacies, clinics, and e-commerce platforms [8]. Competitive Landscape - The market is becoming increasingly competitive with numerous companies entering the field, necessitating continuous innovation and marketing efforts to stand out [13]. - Key players in the industry include ST Xiangxue, China Resources Sanjiu, Kangyuan Pharmaceutical, and others, each with unique product offerings and market strategies [1][13]. Development Trends - There is significant growth potential in the central and rural markets, where the penetration of antiviral oral liquids is currently low due to insufficient medical resources [21]. - Future innovations in nanotechnology and targeted drug delivery systems are expected to enhance product efficacy and reduce side effects, driving further advancements in the industry [22]. - The market is likely to see increased concentration as leading companies leverage technology and brand development to capture larger market shares, while new entrants may adopt innovative strategies to compete [23].